<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2307-3349</journal-id>
<journal-title><![CDATA[Revista de salud publica del Paraguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. salud publica Parag.]]></abbrev-journal-title>
<issn>2307-3349</issn>
<publisher>
<publisher-name><![CDATA[INSTITUTO NACIONAL DE SALUD - MSP Y BS]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2307-33492021000200024</article-id>
<article-id pub-id-type="doi">10.18004/rspp.2021.diciembre.24</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos secundarios de las vacunas anti COVID-19 en personal de salud de Paraguay: estudio exploratorio]]></article-title>
<article-title xml:lang="en"><![CDATA[Side effects of COVID-19 vaccines in paraguayan health personnel: exploratory study]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rios-González]]></surname>
<given-names><![CDATA[Carlos Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendez]]></surname>
<given-names><![CDATA[Julieta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estigarribia]]></surname>
<given-names><![CDATA[Gladys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[Gloria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Caaguazú Facultad de Ciencias Médicas Dirección de Investigación]]></institution>
<addr-line><![CDATA[Coronel Oviedo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Caaguazú Instituto Regional de Investigación en Salud ]]></institution>
<addr-line><![CDATA[Coronel Oviedo ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>11</volume>
<numero>2</numero>
<fpage>24</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2307-33492021000200024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2307-33492021000200024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2307-33492021000200024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Paraguay empezó el lunes 22 de febrero de 2021 la campaña de vacunación contra el COVID-19. Todas las vacunas, incluidas las de COVID-19, conllevan la posibilidad de efectos secundarios entre los principales se encuentra: fatiga, fiebre, cefalea, mialgias, escalofríos, náuseas, diarrea y dolor en el lugar de la inyección.  Objetivo: Identificar la proporción de efectos secundarios de las vacunas contra COVID-19 en personal de salud de Paraguay durante el 2021  Metodología:  Estudio observacional, descriptivo, de corte transversal. La población lo constituyeron el personal de salud vacunado por COVID-19 en el primer trimestre del año 2021. Las variables estudiadas fueron sexo, edad, antecedente de covid-19, enfermedades de base, el nombre de la vacuna recibida, los síntomas, el tiempo de aparición de síntomas y la duración de los mismos, uso de paracetamol y si precisó o no atención médica.  Resultados:  Fueron incluidos 146 participantes en el estudio, de los cuales el 68.5% fue del sexo femenino y el 38.4% tenía menos de 30 años. El 72.6% de los participantes recibió la vacuna Oxford-Astrazeneca y el 76.1% no tuvo antecedente de COVD-19. El 60.4% de la población de estudio tuvo síntomas posteriores a la vacunación de COVID-19. Los síntomas más comunes fueron el dolor de brazo (84.1%) debilidad/fatiga (75.9%), dolor de cabeza (65.5%), dolor articular (48.8%), escalofríos (41.4%), fiebre (39.1%) y náuseas (33.3). El tiempo de inicio de síntomas fue inmediato (hasta 1 hora después de la vacunación) mayormente 43.3% en la vacuna Oxford-AstraZeneca comparado con las demás vacunas (11.8%). Los síntomas duraron 1 día en el 42.9% de los casos.  Conclusión: La frecuencia de efectos secundarios fue en 60.4% de la población, sin embargo, los síntomas fueron leves y en su mayoría duraron un día posterior a la aplicación. La vigilancia en la población general es necesaria en esta etapa durante el lanzamiento de la vacunación.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Paraguay began on monday, february 22, 2021, the vaccination campaign against covid-19. All vaccines, including those for COVID-19, carry the potential for side effects such as fatigue, fever, headaches, myalgia, chills, nausea, diarrhea, and injection site pain.  Objective: Identify the proportion of side effects of vaccines against COVID-19 in health personnel in Paraguay.  Methodology: Cross-sectional study. The population was made up of health personnel vaccinated by COVID-19 in the first quarter of 2021. The variables were sex, age, history of COVID-19, underlying diseases, the name of the vaccine received, symptoms, time of appearance of symptoms and their duration, use of paracetamol and whether or not medical attention was required.  Results: 146 participated, of which 68.5% were female and 38.4% were less than 30 years old. 72.6% of the participants received the Oxford-AstraZeneca vaccine and 76.1% had no history of Covid-19. 60.4% of the study population had symptoms after COVID-19 vaccination. The most common symptoms were arm pain (84.1%) weakness / fatigue (75.9%), headache (65.5%), joint pain (48.8%), chills (41.4%), fever (39.1%), and nausea (33.3). The time to onset of symptoms was immediate (up to 1 hour after vaccination), mostly 43.3% in the Oxford-AstraZeneca vaccine compared to the other vaccines (11.8%). Symptoms lasted 1 day in 42.9% of cases.  Conclusion:  The frequency of side effects was 60.4% of the population, however, the symptoms were mild and mostly lasted one day after the application. Surveillance in the general population is necessary at this stage during the launch of vaccination]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[vacuna]]></kwd>
<kwd lng="es"><![CDATA[AstraZeneca]]></kwd>
<kwd lng="es"><![CDATA[síntomas]]></kwd>
<kwd lng="es"><![CDATA[efectos secundarios]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[vaccine]]></kwd>
<kwd lng="en"><![CDATA[AstraZeneca]]></kwd>
<kwd lng="en"><![CDATA[symptoms]]></kwd>
<kwd lng="en"><![CDATA[side effects]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ríos-González]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implicancias del COVID-19, una nueva enfermedad producida por Coronavirus.]]></article-title>
<source><![CDATA[Med. Clín. Soc.]]></source>
<year>2019</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>71-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Vacuna contra COVID-19.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Soto]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the Moderna, Pfizer/BioNtech, Astrazeneca/Oxford and Sputnik V Vaccines for COVID-19]]></article-title>
<source><![CDATA[OSF Preprints]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Ciencias del Sur</collab>
<source><![CDATA[¿Qué sabemos sobre las Vacunas COVID-19 que tenemos en Paraguay?]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voysey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[SAC]]></given-names>
</name>
<name>
<surname><![CDATA[Madhi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Weckx]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Folegatti]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Aley]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2021</year>
<volume>10269</volume>
<page-range>99-111</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faranda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Arutkin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lembo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lucarini]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: the AstraZeneca case for France and Italy.]]></article-title>
<source><![CDATA[ArXiv210314904 Phys Q-Bio]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baraniuk]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19: What do we know about Sputnik V and other Russian vaccines?]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
<page-range>743</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ríos-González]]></surname>
<given-names><![CDATA[CM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predisposición para recibir la vacuna contra el COVID-19 en Paraguay: estudio exploratorio online.]]></article-title>
<source><![CDATA[Med. clín. soc.]]></source>
<year>2021</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>119-20</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial.]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kupferschmidt]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Side effect worry grows for AstraZeneca vaccine.]]></article-title>
<source><![CDATA[Science]]></source>
<year>2021</year>
<volume>372</volume>
<numero>6537</numero>
<issue>6537</issue>
<page-range>14-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torjesen]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
<page-range>295</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
<page-range>326</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Phatak]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bhattacharjee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody Response after First-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study.]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hitchings]]></surname>
<given-names><![CDATA[MDT]]></given-names>
</name>
<name>
<surname><![CDATA[Ranzani]]></surname>
<given-names><![CDATA[OT]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[MSS]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[SB de]]></given-names>
</name>
<name>
<surname><![CDATA[Almiron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Said]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study.]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagotto]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ferloni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Golde]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Active Surveillance Of The Sputnik V Vaccine In Health Workers.]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Logunov]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Dolzhikova]]></surname>
<given-names><![CDATA[IV]]></given-names>
</name>
<name>
<surname><![CDATA[Shcheblyakov]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Tukhvatulin]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Zubkova]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Dzharullaeva]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10275</numero>
<issue>10275</issue>
<page-range>671-81</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Østergaard]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Horváth-Puhó]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Sørensen]]></surname>
<given-names><![CDATA[HT.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10283</numero>
<issue>10283</issue>
<page-range>1441-3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Motta]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can a COVID-19 vaccine live up to Americans&#8217; expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions. Social]]></article-title>
<source><![CDATA[Science &amp; Medicine]]></source>
<year>2021</year>
<volume>272</volume>
<page-range>113642</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahase]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safety.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2021</year>
<volume>372</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
